Benchmark has reaffirmed its Buy rating for Insulet Corporation's stock despite the recent recall of certain products. The firm has assessed the situation and determined that the recall will not significantly impact the company's long-term growth prospects. Analysts at Benchmark continue to express confidence in Insulet's market position and future performance. The stock remains a recommended investment choice for those looking to capitalize on the company's potential.
Don't miss out on breaking stories and in-depth articles.
